Tag: safety

FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced a one-for-thirty reverse stock split (the “Reverse Stock Split”) of the company’s common stock, par value $0.00001, which will become effective at 12:01 a.m. Eastern Time on Tuesday, June 24, 2025. The company’s common stock will continue to trade under its current trading symbol, CLRB, on the Nasdaq Global Select Market (“Nasdaq”) on a split-adjusted basis when the market opens on Tuesday, June 24, 2025, with the new CUSIP number 15117F880.

Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors

Nearly 8,000 team members were honored, representing over 55,000 combined years of safety excellence

Aliso Viejo, CA , June 18, 2025 (GLOBE NEWSWIRE) -- Galacxia, Inc., developer of the Life Backup Plan digital health platform, proudly announces its advancement to the second round of Pepperdine University’s Most Fundable Companies® 2025 competition. The company earned a “B” rating, reflecting “Great Potential” among a competitive national pool of startups evaluated for scalability, business fundamentals, and investor appeal.

JOHANNESBURG, June 18, 2025 (GLOBE NEWSWIRE) -- Renergen is pleased to announce that preferred bidder status has been awarded to He4u consortium for the design, procurement, delivery, construction and commissioning for phase 2 of the Tetra4 LNG and helium liquefaction project, comprising of, Chart Industries Inc. (NYSE: GTLS), Wilson Bayly Holmes - Ovcon Ltd (JSE: WBO), and Aurex Constructors. The appointment of an acceptable EPC contractor in Phase 2 was one of the two remaining conditions for the DFC Phase 2 loan.